Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistTurbare Manufacturing, an outsourcing facility registered to compound sterile drugs, was cited for serious deficiencies in its sterile drug manufacturing practices that put patients at risk during an FDA inspection conducted January 14-24, 2025. The facility produced Bevacizumab products that violated the Federal Food, Drug, and Cosmetic Act due to lack of sterility assurance, prompting the company to voluntarily recall two lots in February 2025. The FDA found that Turbare Manufacturing's compounding practices failed to meet the conditions required for outsourcing facilities to qualify for drug approval exemptions under section 503B of the FDCA.